

ASX/Media Release

RESULTS OF ANNUAL GENERAL MEETING

SYDNEY, AUSTRALIA – 27 November, 2025 – [Immutech Limited](#) (ASX: IMM; NASDAQ: IMMP) (“Immutech” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today advises that the results of its Annual General Meeting (AGM) are set out in the attached document in accordance with section 251AA(2) of the *Corporations Act 2001* (Cth) and Listing Rule 3.13.2.

Please be advised that all resolutions in the Company’s 2025 Notice of Annual General Meeting were passed by the requisite majorities at today’s AGM.

All resolutions were passed and decided by way of poll.

About Immutech

Immutech is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutech is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutech.com.

Australian Investors/Media:

Eleanor Pearson, Sodali & Co.

+61 2 9066 4071; eleanor.pearson@sodali.com

U.S. Investors/Media:

Chris Basta, VP, Investor Relations and Corporate Communications

+1 (631) 318 4000; chris.basta@immunech.com

This announcement was authorised for release by Indira Naidu, Company Secretary of Immutech Limited.



Immutep Limited
Annual General Meeting
Thursday, 27 November 2025
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. Adoption of the Remuneration Report	Ordinary	533,861,328 86.97%	77,621,151 12.65%	2,329,671 0.38%	1,551,240	540,855,090 87.45%	77,621,151 12.55%	1,551,240	Carried	No
2. Re-election of Director - Mr Pete Meyers	Ordinary	594,805,468 96.86%	16,836,439 2.74%	2,420,625 0.39%	12,654,622	602,146,805 97.28%	16,836,439 2.72%	12,654,622	Carried	N/A
3. Approval of Grant of Performance Rights to Mr Pete Meyers	Ordinary	597,790,595 97.71%	11,593,468 1.90%	2,393,377 0.39%	14,939,714	604,848,063 98.12%	11,593,468 1.88%	14,939,714	Carried	N/A
4. Approval of Grant of Performance Rights to Dr Russell Howard	Ordinary	597,786,709 97.72%	11,472,344 1.88%	2,453,377 0.40%	15,004,724	604,904,177 98.14%	11,472,344 1.86%	15,004,724	Carried	N/A
5. Approval of Grant of Performance Rights to Ms Lis Boyce	Ordinary	597,806,097 97.73%	11,482,388 1.88%	2,393,377 0.39%	15,035,292	604,863,565 98.14%	11,482,388 1.86%	15,035,292	Carried	N/A

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.